FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody, or its antigen-binding fragment, which binds to a protein, Epsin-1 (EPN1), as well as to a conjugate and a composition containing it. Also disclosed is an isolated nucleic acid molecule encoding a VHC antibody or an antigen-binding fragment thereof, recovered nucleic acid molecule coding VLC antibody or its antigen-binding fragment, as well as vector and cell containing same.
EFFECT: invention is effective for inhibiting growth or dissemination of tumor containing cells expressing EPN1, as well as for treating oncological disease or a hyperplastic disorder containing cells expressing EPN1.
26 cl, 17 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| COMPOSITIONS AND METHODS OF ACTIVATING INTEGRINS | 2020 |
|
RU2836262C1 |
